Study of Human Interleukin 12 (IL-12), Human Interleukin 3 (IL-3) and Interferon gamma (IFN-γ) in patients with COVID-19 in Wasit Province, Iraq

Abstract

In late December 2019, a small number of patients with mysterious fever and signs of lower respiratory tract infections were discovered in Wuhan, China's Hubei province's largest metropolitan city. It was originally identified as pneumonia of unclear etiology because the etiology of this unknown respiratory infection could not be determined. The causative pathogen was identified and designated 2019 novel coronavirus after further investigation by the local authority of the Chinese Center for Disease Control and Prevention. (2019- nCoV). COVID-19, the acronym for "coronavirus disease2019," was announced on February11, 2020 as the disease caused by this new coronavirus. Coronavirus 2 causes severe acute respiratory syndrome  (SARS-CoV-2, SARS2, 2019-nCoV or COVID-19 virus), This pathogen causes a syndrome that can lead to a critical care respiratory condition, which requires specialized treatment of certain intensive care units (ICUs).

A study was conducted to study some immunological markers in patients with COVID-19 between patient and control in Wasit province. The results showed a highly significant increase in the IL-12 (62.03%)  , IL-3(93.80%)  and IFN-γ(13.16%) for patient that have COVID-19 and this results was Compared with controls and this study was  divided  according to age groups for patients and results  showed the highest value for patients that age lowest 40 IL-12 (12.72), IL-3 (94.77) and IFN-γ (64.35) compared with patients that age highest than 40.